ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer

July 9, 2020

-ImCheck Therapeutics Appoints Claude Knopf as Chief Business Officer

-First hire in the US will support growing global business development activities

Marseille, France, July 9, 2020 – ImCheck Therapeutics today announced the appointment of Claude Knopf as Chief Business Officer. Mr. Knopf brings over 25 years of experience as a senior business development executive from both large pharmaceutical and emerging biotechnology companies, with a recent focus on transactions and collaborations in the areas of immunology and oncology.

With the appointment of Mr. Knopf, ImCheck has initiated the expansion of its corporate activities into the United States, a strategic step supporting ongoing business development efforts. Mr. Knopf will be based in Boston, Massachusetts, giving ImCheck access to a key hub of the biopharmaceutical industry as the company further establishes itself as an emerging immuno-oncology (IO) leader developing a deep pipeline of antibody drug candidates targeting the butyrophilin (BTN) superfamily of immune system regulators.

“Claude brings us a strong track record in driving value-generating business development initiatives and completes our leadership team, who all have both large pharma and innovative small biotechnology backgrounds,” stated Pierre d’Epenoux, Chief Executive Officer of ImCheck Therapeutics. “His contributions to corporate strategy as well as leading negotiations for collaborations and licensing will be a vital part of our growth, including kicking-off ImCheck’s activities in the US.”

Full press release can be found here.